(Q46512353)

22 December 2017

title

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab (English)

1 reference

22 December 2017

author name string

A Chan

series ordinal

1

1 reference

22 December 2017

S R McGregor

series ordinal

2

1 reference

22 December 2017

publication date

1 March 2012

1 reference

22 December 2017

Internal Medicine Journal

published in

1 reference

22 December 2017

volume

42

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

267-274

1 reference

22 December 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02432.X

10.1111/J.1445-5994.2011.02432.X

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017